Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Dietary saturated fatty acids reverse inflammatory and fibrotic changes in rat liver despite continued ethanol administration.

Nanji AA, Jokelainen K, Tipoe GL, Rahemtulla A, Dannenberg AJ.

J Pharmacol Exp Ther. 2001 Nov;299(2):638-44.

2.

Dietary saturated fatty acids down-regulate cyclooxygenase-2 and tumor necrosis factor alfa and reverse fibrosis in alcohol-induced liver disease in the rat.

Nanji AA, Zakim D, Rahemtulla A, Daly T, Miao L, Zhao S, Khwaja S, Tahan SR, Dannenberg AJ.

Hepatology. 1997 Dec;26(6):1538-45.

PMID:
9397995
3.

Arginine reverses ethanol-induced inflammatory and fibrotic changes in liver despite continued ethanol administration.

Nanji AA, Jokelainen K, Lau GK, Rahemtulla A, Tipoe GL, Polavarapu R, Lalani EN.

J Pharmacol Exp Ther. 2001 Dec;299(3):832-9.

4.

Increased severity of alcoholic liver injury in female rats: role of oxidative stress, endotoxin, and chemokines.

Nanji AA, Jokelainen K, Fotouhinia M, Rahemtulla A, Thomas P, Tipoe GL, Su GL, Dannenberg AJ.

Am J Physiol Gastrointest Liver Physiol. 2001 Dec;281(6):G1348-56.

5.

Thromboxane inhibitors attenuate inflammatory and fibrotic changes in rat liver despite continued ethanol administrations.

Nanji AA, Liong EC, Xiao J, Tipoe GL.

Alcohol Clin Exp Res. 2013 Jan;37(1):31-9. doi: 10.1111/j.1530-0277.2012.01838.x.

6.

Curcumin prevents alcohol-induced liver disease in rats by inhibiting the expression of NF-kappa B-dependent genes.

Nanji AA, Jokelainen K, Tipoe GL, Rahemtulla A, Thomas P, Dannenberg AJ.

Am J Physiol Gastrointest Liver Physiol. 2003 Feb;284(2):G321-7.

8.
9.

A voluntary oral ethanol-feeding rat model associated with necroinflammatory liver injury.

Tipoe GL, Liong EC, Casey CA, Donohue TM Jr, Eagon PK, So H, Leung TM, Fogt F, Nanji AA.

Alcohol Clin Exp Res. 2008 Apr;32(4):669-82. doi: 10.1111/j.1530-0277.2008.00623.x.

PMID:
18341647
10.

Activation of nuclear factor kappa B and cytokine imbalance in experimental alcoholic liver disease in the rat.

Nanji AA, Jokelainen K, Rahemtulla A, Miao L, Fogt F, Matsumoto H, Tahan SR, Su GL.

Hepatology. 1999 Oct;30(4):934-43.

PMID:
10498645
11.

Medium chain triglycerides and vitamin E reduce the severity of established experimental alcoholic liver disease.

Nanji AA, Yang EK, Fogt F, Sadrzadeh SM, Dannenberg AJ.

J Pharmacol Exp Ther. 1996 Jun;277(3):1694-700.

PMID:
8667240
13.

Enhanced cyclooxygenase-2 gene expression in alcoholic liver disease in the rat.

Nanji AA, Miao L, Thomas P, Rahemtulla A, Khwaja S, Zhao S, Peters D, Tahan SR, Dannenberg AJ.

Gastroenterology. 1997 Mar;112(3):943-51.

PMID:
9041257
14.

Dietary saturated fatty acids: a novel treatment for alcoholic liver disease.

Nanji AA, Sadrzadeh SM, Yang EK, Fogt F, Meydani M, Dannenberg AJ.

Gastroenterology. 1995 Aug;109(2):547-54.

PMID:
7615205
16.

Voluntary oral feeding of rats not requiring a very high fat diet is a clinically relevant animal model of non-alcoholic fatty liver disease (NAFLD).

Tipoe GL, Ho CT, Liong EC, Leung TM, Lau TY, Fung ML, Nanji AA.

Histol Histopathol. 2009 Sep;24(9):1161-9. doi: 10.14670/HH-24.1161.

PMID:
19609863
17.
18.

Acetaldehyde prevents nuclear factor-kappa B activation and hepatic inflammation in ethanol-fed rats.

Lindros KO, Jokelainen K, Nanji AA.

Lab Invest. 1999 Jul;79(7):799-806.

PMID:
10418820
19.

Cholesterol supplementation prevents necrosis and inflammation but enhances fibrosis in alcoholic liver disease in the rat.

Nanji AA, Rahemtulla A, Daly T, Khwaja S, Miao L, Zhao S, Tahan SR.

Hepatology. 1997 Jul;26(1):90-7.

PMID:
9214456
20.

Ascorbic acid suppresses endotoxemia and NF-κB signaling cascade in alcoholic liver fibrosis in guinea pigs: a mechanistic approach.

Abhilash PA, Harikrishnan R, Indira M.

Toxicol Appl Pharmacol. 2014 Jan 15;274(2):215-24. doi: 10.1016/j.taap.2013.11.005.

PMID:
24239723

Supplemental Content

Support Center